BACKGROUND: Matrix metalloproteinases are best recognized for their ability to degrade the extracellular matrix in both physiological and pathological conditions. However, recent findings indicate that some of them are also involved in mediating acute processes such as platelet aggregation and vascular tone. The acute contractile defect of the heart after ischemia-reperfusion may involve the proteolytic degradation of the thin filament protein troponin I; however, the protease responsible for this remains obscure. METHODS AND RESULTS: Here we report that matrix metalloproteinase-2 is colocalized with troponin I within the thin myofilaments of cardiomyocytes in ischemic-reperfused hearts and that troponin I is a novel intracellular target for proteolytic cleavage by matrix metalloproteinase-2. Inhibition of matrix metalloproteinase-2 activity prevented ischemia-reperfusion-induced troponin I degradation and improved the recovery of mechanical function of the heart. CONCLUSIONS: These data reveal for the first time a novel molecular mechanism by which matrix metalloproteinase-2 causes acute myocardial dysfunction after ischemia-reperfusion-injury and that matrix metalloproteinase-2 has a biological action within the cell.
BACKGROUND: Matrix metalloproteinases are best recognized for their ability to degrade the extracellular matrix in both physiological and pathological conditions. However, recent findings indicate that some of them are also involved in mediating acute processes such as platelet aggregation and vascular tone. The acute contractile defect of the heart after ischemia-reperfusion may involve the proteolytic degradation of the thin filament protein troponin I; however, the protease responsible for this remains obscure. METHODS AND RESULTS: Here we report that matrix metalloproteinase-2 is colocalized with troponin I within the thin myofilaments of cardiomyocytes in ischemic-reperfused hearts and that troponin I is a novel intracellular target for proteolytic cleavage by matrix metalloproteinase-2. Inhibition of matrix metalloproteinase-2 activity prevented ischemia-reperfusion-induced troponin I degradation and improved the recovery of mechanical function of the heart. CONCLUSIONS: These data reveal for the first time a novel molecular mechanism by which matrix metalloproteinase-2 causes acute myocardial dysfunction after ischemia-reperfusion-injury and that matrix metalloproteinase-2 has a biological action within the cell.
Authors: Thomas S Metkus; Eliseo Guallar; Lori Sokoll; David Morrow; Gordon Tomaselli; Roy Brower; Steven Schulman; Frederick K Korley Journal: Crit Care Med Date: 2017-10 Impact factor: 7.598
Authors: Aram J Raissi; Frank A Scangarello; Kaitlin R Hulce; Jason K Pontrello; Suzanne Paradis Journal: Bioorg Med Chem Lett Date: 2014-02-14 Impact factor: 2.823
Authors: Hui-Zhong Zhou; Xiaokui Ma; Mary O Gray; Bo-qing Zhu; Anita P Nguyen; Anthony J Baker; Ursula Simonis; Gary Cecchini; David H Lovett; Joel S Karliner Journal: Biochem Biophys Res Commun Date: 2007-04-23 Impact factor: 3.575
Authors: Karni S Moshal; Srinivas M Tipparaju; Thomas P Vacek; Munish Kumar; Mahavir Singh; Iluiana E Frank; Phani K Patibandla; Neetu Tyagi; Jayesh Rai; Naira Metreveli; Walter E Rodriguez; Michael T Tseng; Suresh C Tyagi Journal: Am J Physiol Heart Circ Physiol Date: 2008-06-20 Impact factor: 4.733